Skip to main
ANRO
ANRO logo

ANRO Stock Forecast & Price Target

ANRO Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 14%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Alto Neuroscience Inc has achieved significant advancements in its clinical-stage assets, particularly with ALTO-207, which is noted for its improved tolerability compared to pramipexole, allowing for higher doses and faster titration in treating depressive symptoms. The company's financial performance reflects this progress, as ALTO-207 generated $1.08 billion in revenue for FY24, marking a substantial 60% increase from FY23. Additionally, the development of a new transdermal formulation for ALTO-101, which has shown an enhanced safety profile and promising pharmacokinetics, further supports the positive outlook on the effectiveness of Alto's precision psychiatry pipeline.

Bears say

Alto Neuroscience Inc has experienced significant stock pressure since its initial public offering in 2024, primarily due to the failure of its lead asset, ALTO-100, in a crucial Phase 2b study for major depressive disorder. The failure not only undermined confidence in the company's core strategy but also raised concerns regarding the efficacy of its ongoing programs, including a Phase 2b study in bipolar depression, which is characterized by a low probability of success. Furthermore, the company's focus on neurobiology and biomarkers, while innovative, has faced challenges given the complexities of deficits in neuroplasticity that can exacerbate treatment resistance and negative outcomes in patients, significantly impacting its overall investment appeal.

ANRO has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 14% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alto Neuroscience Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alto Neuroscience Inc (ANRO) Forecast

Analysts have given ANRO a Strong Buy based on their latest research and market trends.

According to 7 analysts, ANRO has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alto Neuroscience Inc (ANRO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.